News for Healthier Living

Phase 2 BESTOW Trial Generates Promising Kidney Function and Quality of Life Results for Tegoprubart Versus Tacrolimus Immunosuppression in Kidney Transplant Recipients

The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.

October 23, 2026


October 24 2026

October 23 2026

October 22 2026

October 21 2026

October 20 2026

October 19 2026

October 18 2026

October 17 2026

October 16 2026

October 15 2026

October 14 2026

October 13 2026

October 12 2026

October 11 2026

October 10 2026